Carbylan Therapeutics CEO T Crockett's 2019 pay jumps 61% to $3.3M
Carbylan Therapeutics reports 2019 executive compensation
By ExecPay News
Published: August 23, 2019
Carbylan Therapeutics reported fiscal year 2019 executive compensation information on August 23, 2019.
In 2019, three executives at Carbylan Therapeutics received on average a compensation package of $2.3M, a 62% increase compared to previous year.
T. Andrew Crockett, Chief Executive Officer, received $3.3M in total, which increased by 61% compared to 2018. 73.55% of Crockett's compensation, or $2.4M, was in option awards. Crockett also received $353.5K in bonus, $505K in salary, as well as $11K in other compensation.
Benjamin L. Palleiko, Chief Financial Officer, received a compensation package of $2.1M, which increased by 155% compared to previous year. 47.55% of the compensation package, or $994.6K, was in option awards.
Edward P. Feener, Chief Scientific Officer, earned $1.6M in 2019.
Carbylan Therapeutics' fiscal year ends on April 30.